KATIA RAMOS MOREIRA LEITE
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cirurgia, Faculdade de Medicina - Docente
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/26 - Laboratório de Pesquisa em Cirurgia Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/26 - Laboratório de Pesquisa em Cirurgia Experimental, Hospital das Clínicas, Faculdade de Medicina
19 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 19
- Utility of Pathology Imagebase for standardisation of prostate cancer grading(2018) EGEVAD, Lars; DELAHUNT, Brett; BERNEY, Daniel M.; BOSTWICK, David G.; CHEVILLE, John; COMPERAT, Eva; EVANS, Andrew J.; FINE, Samson W.; GRIGNON, David J.; HUMPHREY, Peter A.; HORNBLAD, Jonas; ICZKOWSKI, Kenneth A.; KENCH, James G.; KRISTIANSEN, Glen; LEITE, Katia R. M.; MAGI-GALLUZZI, Cristina; MCKENNEY, Jesse K.; OXLEY, Jon; PAN, Chin-Chen; SAMARATUNGA, Hemamali; SRIGLEY, John R.; TAKAHASHI, Hiroyuki; TRUE, Lawrence D.; TSUZUKI, Toyonori; KWAST, Theo van der; VARMA, Murali; ZHOU, Ming; CLEMENTS, MarkAimsDespite efforts to standardise grading of prostate cancer, even among experts there is still a considerable variation in grading practices. In this study we describe the use of Pathology Imagebase, a novel reference image library, for setting an international standard in prostate cancer grading. Methods and resultsThe International Society of Urological Pathology (ISUP) recently launched a reference image database supervised by experts. A panel of 24 international experts in prostate pathology reviewed independently microphotographs of 90 cases of prostate needle biopsies with cancer. A linear weighted kappa of 0.67 (95% confidence interval = 0.62-0.72) and consensus was reached in 50 cases. The interobserver weighted kappa varied from 0.48 to 0.89. The highest level of agreement was seen for Gleason score (GS) 3 + 3 = 6 (ISUP grade 1), while higher grades and particularly GS 4 + 3 = 7 (ISUP grade 3) showed considerable disagreement. Once a two-thirds majority was reached, images were moved automatically into a public database available for all ISUP members at . Non-members are able to access a limited number of cases. ConclusionsIt is anticipated that the database will assist pathologists to calibrate their grading and, hence, decrease interobserver variability. It will also help to identify instantces where definitions of grades need to be clarified.
- Low-grade prostate cancer should still be labelled cancer Comment(2022) ICZKOWSKI, Kenneth A.; MOLINA, Mariel; EGEVAD, Lars; BOSTWICK, David G.; LEENDERS, Geert J. L. H. van; ROSA, Francisco G. La; KWAST, Theodorus van der; BERNEY, Daniel M.; EVANS, Andrew J.; WHEELER, Thomas M.; LEITE, Katia R. M.; SAMARATUNGA, Hemamali; SRIGLEY, John; VARMA, Murali; TSUZUKI, Toyonori; LUCIA, Marshall Scott; CRAWFORD, Elward David; HARRIS, Richard G.; STRICKER, Philip; LAWRENTSCHUK, Nathan; WOO, Henry H.; FLESHNER, Neil E.; SHORE, Neal D.; YAXLEY, John; BRATT, Ola; WIKLUND, Peter; ROBERTS, Matthew; CHENG, Liang; DELAHUNT, Brett
- Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria(2023) EGEVAD, Lars; DELAHUNT, Brett; ICZKOWSKI, Kenneth A.; KWAST, Theo van der; LEENDERS, Geert J. L. H. van; LEITE, Katia R. M.; PAN, Chin-Chen; SAMARATUNGA, Hemamali; TSUZUKI, Toyonori; MULLIQI, Nita; JI, Xiaoyi; OLSSON, Henrik; VALKONEN, Masi; RUUSUVUORI, Pekka; EKLUND, Martin; KARTASALO, KimmoAimsThere is strong evidence that cribriform morphology indicates a worse prognosis of prostatic adenocarcinoma. Our aim was to investigate its interobserver reproducibility in prostate needle biopsies. Methods and resultsA panel of nine prostate pathology experts from five continents independently reviewed 304 digitised biopsies for cribriform cancer according to recent International Society of Urological Pathology criteria. The biopsies were collected from a series of 702 biopsies that were reviewed by one of the panellists for enrichment of high-grade cancer and potentially cribriform structures. A 2/3 consensus diagnosis of cribriform and noncribriform cancer was reached in 90% (272/304) of the biopsies with a mean kappa value of 0.56 (95% confidence interval 0.52-0.61). The prevalence of consensus cribriform cancers was estimated to 4%, 12%, 21%, and 20% of Gleason scores 7 (3 + 4), 7 (4 + 3), 8, and 9-10, respectively. More than two cribriform structures per level or a largest cribriform mass with >= 9 lumina or a diameter of >= 0.5 mm predicted a consensus diagnosis of cribriform cancer in 88% (70/80), 84% (87/103), and 90% (56/62), respectively, and noncribriform cancer in 3% (2/80), 5% (5/103), and 2% (1/62), respectively (all P < 0.01). ConclusionCribriform prostate cancer was seen in a minority of needle biopsies with high-grade cancer. Stringent diagnostic criteria enabled the identification of cribriform patterns and the generation of a large set of consensus cases for standardisation.
- Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study(2020) STROM, Peter; KARTASALO, Kimmo; OLSSON, Henrik; SOLORZANO, Leslie; DELAHUNT, Brett; BERNEY, Daniel M.; BOSTWICK, David G.; EVANS, Andrew J.; GRIGNON, David J.; HUMPHREY, Peter A.; ICZKOWSKI, Kenneth A.; KENCH, James G.; KRISTIANSEN, Glen; KWAST, Theodorus H. van der; LEITE, Katia R. M.; MCKENNEY, Jesse K.; OXLEY, Jon; PAN, Chin-Chen; SAMARATUNGA, Hemamali; SRIGLEY, John R.; TAKAHASHI, Hiroyuki; TSUZUKI, Toyonori; VARMA, Murali; ZHOU, Ming; LINDBERG, Johan; LINDSKOG, Cecilia; RUUSUVUORI, Pekka; WAHLBY, Carolina; GRONBERG, Henrik; RANTALAINEN, Mattias; EGEVAD, Lars; EKLUND, MartinBackground An increasing volume of prostate biopsies and a worldwide shortage of urological pathologists puts a strain on pathology departments. Additionally, the high intra-observer and inter-observer variability in grading can result in overtreatment and undertreatment of prostate cancer. To alleviate these problems, we aimed to develop an artificial intelligence (AI) system with clinically acceptable accuracy for prostate cancer detection, localisation, and Gleason grading. Methods We digitised 6682 slides from needle core biopsies from 976 randomly selected participants aged 50-69 in the Swedish prospective and population-based STHLM3 diagnostic study done between May 28,2012, and Dec 30,2014 (ISRCTN84445406), and another 271 from 93 men from outside the study. The resulting images were used to train deep neural networks for assessment of prostate biopsies. The networks were evaluated by predicting the presence, extent, and Gleason grade of malignant tissue for an independent test dataset comprising 1631 biopsies from 246 men from STHLM3 and an external validation dataset of 330 biopsies from 73 men. We also evaluated grading performance on 87 biopsies individually graded by 23 experienced urological pathologists from the International Society of Urological Pathology. We assessed discriminatory performance by receiver operating characteristics and tumour extent predictions by correlating predicted cancer length against measurements by the reporting pathologist. We quantified the concordance between grades assigned by the AI system and the expert urological pathologists using Cohen's kappa. Findings The AI achieved an area under the receiver operating characteristics curve of 0.997 (95% CI 0.994-0.999) for distinguishing between benign (n=910) and malignant (n=721) biopsy cores on the independent test dataset and 0.986 (0.972-0.996) on the external validation dataset (benign n=108, malignant n=222). The correlation between cancer length predicted by the AI and assigned by the reporting pathologist was 0.96 (95% CI 0.95-0.97) for the independent test dataset and 0.87 (0.84-0.90) for the external validation dataset. For assigning Gleason grades, the AI achieved a mean pairwise kappa of 0.62, which was within the range of the corresponding values for the expert pathologists (0.60-0.73). Interpretation An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking comparable to that of international experts in prostate pathology. Clinical application could reduce pathology workload by reducing the assessment of benign biopsies and by automating the task of measuring cancer length in positive biopsy cores. An AI system with expert-level grading performance might contribute a second opinion, aid in standardising grading, and provide pathology expertise in parts of the world where it does not exist.
- Distinct urinary glycoprotein signatures in prostate cancer patients(2018) KAWAHARA, R.; ORTEGA, F.; ROSA-FERNANDES, L.; GUIMARãES, V.; QUINA, D.; NAHAS, W.; SCHWäMMLE, V.; SROUGI, M.; LEITE, K. R. M.; THAYSEN-ANDERSEN, M.; LARSEN, M. R.; PALMISANO, G.Novel biomarkers are needed to complement prostate specific antigen (PSA) in prostate cancer (PCa) diagnostic screening programs. Glycoproteins represent a hitherto largely untapped resource with a great potential as specific and sensitive tumor biomarkers due to their abundance in bodily fluids and their dynamic and cancer-associated glycosylation. However, quantitative glycoproteomics strategies to detect potential glycoprotein cancer markers from complex biospecimen are only just emerging. Here, we describe a glycoproteomics strategy for deep quantitative mapping of N- and O-glycoproteins in urine with a view to investigate the diagnostic value of the glycoproteome to discriminate PCa from benign prostatic hyperplasia (BPH), two conditions that remain difficult to clinically stratify. Total protein extracts were obtained, concentrated and digested from urine of six PCa patients (Gleason score 7) and six BPH patients. The resulting peptide mixtures were TMT-labeled and mixed prior to a multi-faceted sample processing including hydrophilic interaction liquid chromatography (HILIC) and titanium dioxide SPE based enrichment, endo-/exoglycosidase treatment and HILIC-HPLC pre-fractionation. The isolated N- and O-glycopeptides were detected and quantified using high resolution mass spectrometry. We accurately quantified 729 N-glycoproteins spanning 1,310 unique N-glycosylation sites and observed 954 and 965 unique intact N- and O-glycopeptides, respectively, across the two disease conditions. Importantly, a panel of 56 intact N-glycopeptides perfectly discriminated PCa and BPH (ROC: AUC = 1). This study has generated a panel of intact glycopeptides that has a potential for PCa detection. © Kawahara et al.
- Pathology Imagebase-a reference image database for standardization of pathology(2017) EGEVAD, Lars; CHEVILLE, John; EVANS, Andrew J.; HORNBLAD, Jonas; KENCH, James G.; KRISTIANSEN, Glen; LEITE, Katia R. M.; MAGI-GALLUZZI, Cristina; PAN, Chin-Chen; SAMARATUNGA, Hemamali; SRIGLEY, John R.; TRUE, Lawrence; ZHOU, Ming; CLEMENTS, Mark; DELAHUNT, BrettAims: Despite efforts to standardize histopathology practice through the development of guidelines, the interpretation of morphology is still hampered by subjectivity. We here describe Pathology Imagebase, a novel mechanism for establishing an international standard for the interpretation of pathology specimens. Methods and results: The International Society of Urological Pathology (ISUP) established a reference image database through the input of experts in the field. Three panels were formed, one each for prostate, urinary bladder and renal pathology, consisting of 24 international experts. Each of the panel members uploaded microphotographs of cases into a non-public database. The remaining 23 experts were asked to vote from a multiple-choice menu. Prior to and while voting, panel members were unable to access the results of voting by the other experts. When a consensus level of at least two-thirds or 16 votes was reached, cases were automatically transferred to the main database. Consensus was reached in a total of 287 cases across five projects on the grading of prostate, bladder and renal cancer and the classification of renal tumours and flat lesions of the bladder. The full database is available to all ISUP members at www.isupweb.org. Non-members may access a selected number of cases. Conclusions: It is anticipated that the database will assist pathologists in calibrating their grading, and will also promote consistency in the diagnosis of difficult cases.
- Granular necrosis: a distinctive form of cell death in malignant tumours(2020) SAMARATUNGA, Hemamali; DELAHUNT, Brett; SRIGLEY, John R.; BERNEY, Daniel M.; CHENG, Liang; EVANS, Andrew; FURUSAT, Bungo; LEITE, Katia R. M.; MACLENNAN, Gregory T.; MARTIGNONI, Guido; MOCH, Holger; PAN, Chin-Chen; PANER, Gladell; RO, Jae; THUNDERS, Michelle; TSUZUKI, Toyonori; WHEELER, Thomas; KWAST, Theodorus van der; VARMA, Murali; WILLIAMSON, Sean R.; YAXLEY, John W.; EGEVAD, LarsFoci of necrosis are frequently seen in malignant tumours and may be due to a variety of causes. Different types of necrosis are given various names based upon their morphological features and presumed pathogenesis, such as coagulative, liquefactive and fibrinoid necrosis. Here, we propose the term 'granular necrosis' (GN) for a specific form of tumour necrosis characterised by the presence of well-defined necrotic foci being sharply demarcated from adjacent viable tumour. A constant feature is loss of ar-chitecture resulting in an amorphous necrotic mass containing granular nuclear and cytoplasmic debris, without an associated neutrophilic infiltrate. There is usu-ally extensive karyorrhexis, which in larger tumours is more prominent at the periphery. These foci are often microscopic but may range up to several millimetres or larger in size. This distinctive form of necrosis has been erroneously given a variety of names in the literature including coagulative necrosis and microscopic necrosis, which on the basis of the aforementioned gross and microscopic findings is inappropriate. It is apparent that this is a specific form of necrosis, hence the descriptive term 'granular necrosis' that differentiates this form of ne-crosis from other types. The presence of GN is recognised as occurring in a variety of tumour types, being commonly seen in renal cell carcinoma, where it has been shown to have independent prognostic significance. In some epithelial and stromal tumours of the uterus, the presence of GN also has prognostic significance and is a defining feature for the differentiation of uterine leiomyoma and leiomyosarcoma. The pathogenesis of GN is unresolved. It does not show the features of apoptosis and in recent studies has been shown to have some of the molecular changes associated with necroptosis.
- Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded(2020) SAMARATUNGA, Hemamali; DELAHUNT, Brett; EGEVAD, Lars; SRIGLEY, John R.; BILLIS, Athanase; BOSTWICK, David G.; CAMPARO, Philippe; CHENG, Liang; CLOUSTON, David; DENHAM, James; FURUSATO, Bungo; HARTMANN, Arndt; JUFE, Laura; KENCH, James; KENWRIGHT, Diane N.; KRISTIANSEN, Glen; LEITE, Katia R. M.; MACLENNAN, Gregory T.; MERRIMEN, Jennifer; MOCH, Holger; OXLEY, Jon; PAN, Chin-Chen; PANER, Gladell; RO, Jae; SESTERHENN, Isabell A. M.; SHANKS, Jonathan; THUNDERS, Michelle; TSUZUKI, Toyonori; WHEELER, Thomas; YAXLEY, John W.; VARMA, MuraliInfiltration of the prostatic ducts by prostatic adenocarcinoma occurs relatively frequently, being most commonly associated with high grade disease. It is now recognised that intraductal carcinoma of the prostate (IDCP) has an associated poor prognosis and this is reflected in its histological, molecular and immunohistochemical features. The current recommendation of the World Health Organization is that IDCP not be taken into consideration when grading prostate adenocarcinoma. It is apparent that Gleason did not differentiate between IDCP and stromal invasive carcinoma when developing and validating his grading system, and recent studies suggest that the incorporation of IDCP grading into the overall grading of the specimen provides additional prognostic information.
- International Society of Urological Pathology (ISUP) Grading of Prostate Cancer(2016) EGEVAD, Lars; DELAHUNT, Brett; EVANS, Andrew J.; GRIGNON, David J.; KENCH, James G.; KRISTIANSEN, Glen; LEITE, Katia R.; SAMARATUNGA, Hemamali; SRIGLEY, John R.
- Prostate cancer grading, time to go back to the future(2021) EGEVAD, Lars; DELAHUNT, Brett; BOSTWICK, David G.; CHENG, Liang; EVANS, Andrew J.; GIANDUZZO, Troy; GRAEFEN, Markus; HUGOSSON, Jonas; KENCH, James G.; LEITE, Katia R. M.; OXLEY, Jon; SAUTER, Guido; SRIGLEY, John R.; STATTIN, Par; TSUZUKI, Toyonori; YAXLEY, John; SAMARATUNGA, Hemamali